Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Inclusion Criteria:

* Histologically proven metastatic/unresectable adrenocortical carcinoma or melanoma not amenable to curative surgical or radiation therapy.
* Accrual closed as of 5/27/2009 to patients with renal cell carcinoma
* No squamous cell histology
* No histology in close proximity to a major blood vessel
* No history of or known brain metastases, spinal cord compression, or carcinomatous meningitis
* No new evidence of brain or leptomeningeal disease on screening CT scan or MRI
* ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
* AST and ALT ≤ 2.5 times upper limit of normal (ULN)
* Bilirubin ≤ 1.5 times ULN
* Creatinine ≤ 1.5 times ULN
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥100,000/mm³
* Hemoglobin ≥ 10.0 g/dL
* Calcium ≤ 12.0 mg/dL
* Urine protein:creatinine ratio ≤ 0.5 by urinalysis
* Patients with urine protein:creatinine ratio \> 0.5 must have proteinuria \< 1,000 mg by 24-hour urine collection
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy
* None of the following within the past 12 months:

  * Myocardial infarction
  * Severe/unstable angina
  * Severe peripheral vascular disease (claudication) or procedure on peripheral vasculature
  * Coronary/peripheral artery bypass graft
  * New York Heart Association (NYHA) grade III-IV congestive heart failure
  * Cerebrovascular accident or transient ischemic attack
  * Clinically significant bleeding
  * Deep venous thrombosis
  * Pulmonary embolism
  * No ongoing cardiac dysrhythmias of NCI CTCAE ≥ grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval to \> 450 msec (males) or \> 470 msec (females)
  * No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
  * No condition classified as NYHA grade III or IV
  * No hypertension that cannot be controlled by medications
  * Blood pressure \< 140/90 mm Hg
  * No evidence of bleeding diathesis or coagulopathy
  * No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
  * No history of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening CT or MRI scan unless without progression on \* MRI or CT for 3 months."
  * No significant traumatic injury within the past 28 days
  * No serious, non-healing wound, ulcer, or bone fracture
  * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  * No known HIV or AIDS-related illness
  * No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation.
* Recovered from prior radiation therapy, surgery, or other prior therapy
* No prior bevacizumab or sunitinib malate (SU11248)
* Other antiangiogenic therapies allowed
* No prior tyrosine kinase inhibitor of the VEGF receptor or bevacizumab for patients with metastatic renal cell carcinoma
* No major surgical procedures or open biopsy within the past 28 days
* No core biopsy within the past 7 days
* No radiation therapy or systemic therapy within the past 4 weeks
* No concurrent full-dose anticoagulants (e.g., warfarin)
* Concurrent low-dose anticoagulation (e.g., prophylactic port patency) allowed
* No concurrent treatment on another clinical trial
* No other concurrent investigational drugs
* No concurrent major surgery
* No other concurrent anticancer agents or therapies, including chemotherapy, biological response modifiers, hormonal therapy, surgery, palliative radiation therapy, or immunotherapy